Mission Statement, Vision, & Core Values of Cybin Inc. (CYBN)

What drives a company pushing the boundaries of mental healthcare? The answer lies in its mission, vision, and core values. For example, Cybin Inc., a clinical-stage biopharmaceutical company, reported a cash position of C$136.3 million as of December 31, 2024, and a net loss of C$10.5 million for the quarter ended December 31, 2024, compared to a net loss of C$30.3 million in the same period last year.

But what exactly are the guiding principles behind their work, and how do these values translate into their strategic goals? How do these elements align to drive innovation and impact the future of mental health treatment? Read on to explore the mission, vision, and core values that shape this company's path.

Cybin Inc. (CYBN) An Overview of

Cybin Inc. (CYBN) is a biopharmaceutical company focused on developing psychedelic-based therapeutics to address mental health disorders. Founded in 2019, Cybin operates primarily in Canada and the United States, with research and development activities aimed at creating innovative treatments for conditions like depression, anxiety, and addiction. The company's approach involves discovering and developing proprietary psychedelic molecules, delivery mechanisms, and novel treatment paradigms.

Cybin's product pipeline includes several psilocybin-based programs targeting various mental health conditions. These programs are in different stages of preclinical and clinical development. In addition to drug development, Cybin is involved in research to explore the potential of psychedelic compounds in treating a range of psychological and neurological disorders.

As of April 2025, specific sales figures for Cybin are not readily available. As a development-stage biopharmaceutical company, Cybin primarily focuses on research and clinical trials rather than generating substantial product sales. The company's financial performance is typically evaluated based on its ability to raise capital, advance its clinical programs, and secure partnerships.

Cybin Inc. reported its financial results for the year ended September 30, 2024. Here are some key highlights:

• Revenue: Cybin reported revenue of $0 for the year ended September 30, 2024.
• Net Loss: The company experienced a net loss of $48.2 million for the year ended September 30, 2024, compared to a net loss of $79.2 million for the year ended September 30, 2023.
• Research and Development Expenses: Research and development expenses totaled $25.5 million for the year ended September 30, 2024, a decrease from $41.9 million for the year ended September 30, 2023.
• General and Administrative Expenses: General and administrative expenses amounted to $23.2 million for the year ended September 30, 2024, compared to $37.7 million for the year ended September 30, 2023.
• Cash Position: As of September 30, 2024, Cybin had cash and cash equivalents of $25.1 million.

These figures reflect Cybin's ongoing investment in research and development activities, as well as its efforts to manage operational expenses. The decrease in net loss and R&D expenses suggests a focus on efficiency and strategic resource allocation.

Cybin is positioning itself as a leader in the emerging field of psychedelic therapeutics. Its focus on scientific research, clinical development, and intellectual property protection underscores its commitment to creating safe and effective treatments for mental health conditions. To delve deeper into Cybin Inc.'s financial health and gain more insights, check out: Breaking Down Cybin Inc. (CYBN) Financial Health: Key Insights for Investors.

Cybin Inc. (CYBN) Mission Statement

Cybin Inc. (CYBN) is a biopharmaceutical company focused on progressing psychedelic therapeutics. Its mission is centered on alleviating suffering and enhancing mental well-being through innovative treatments. Cybin Inc. (CYBN): History, Ownership, Mission, How It Works & Makes Money

Core Components of Cybin's Mission Statement

Cybin's mission statement can be broken down into three core components:

• Alleviating Suffering: Addressing mental health conditions such as depression, anxiety, and addiction.
• Enhancing Mental Well-Being: Improving overall psychological health and quality of life.
• Innovative Treatments: Developing novel psychedelic-based therapies through scientific research and clinical trials.

1. Alleviating Suffering

Cybin is dedicated to reducing the burden of mental health disorders, which affect millions of people worldwide. According to the World Health Organization (WHO), depression affects approximately 280 million people globally. Cybin aims to provide effective treatments for these individuals, addressing conditions such as:

• Major Depressive Disorder (MDD)
• Generalized Anxiety Disorder (GAD)
• Substance Use Disorders (SUDs)

Cybin's approach involves rigorous scientific research to develop therapies that target the root causes of these conditions, offering hope for those who have not found relief through traditional treatments.

2. Enhancing Mental Well-Being

Beyond merely treating mental illnesses, Cybin is committed to enhancing overall mental well-being. This involves promoting psychological resilience, emotional balance, and a sense of purpose. Cybin’s strategies include:

• Developing therapies that foster neuroplasticity, allowing the brain to adapt and form new connections.
• Focusing on treatments that improve cognitive function and emotional regulation.
• Supporting research into the potential of psychedelics to promote mindfulness and spiritual well-being.

By enhancing mental well-being, Cybin aims to empower individuals to lead fulfilling and meaningful lives.

3. Innovative Treatments

Innovation is at the heart of Cybin's mission, driving its efforts to develop groundbreaking psychedelic-based therapies. The company employs a multifaceted approach:

• Drug Discovery: Identifying and developing novel psychedelic compounds with enhanced therapeutic properties.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies.
• Intellectual Property: Securing patents and other intellectual property rights to protect its innovations.

As of the fiscal year 2024, Cybin has made significant strides in its clinical programs. For example, its CYB003 program, a deuterated psilocybin analog, is currently in Phase 1/2a clinical trials. The company's commitment to innovation is reflected in its investment in research and development, which totaled $24.6 million for the year ended December 31, 2023.

Cybin's mission is further supported by its strategic partnerships with leading research institutions and pharmaceutical companies. These collaborations enable Cybin to leverage cutting-edge technologies and expertise, accelerating the development of innovative treatments.

Cybin Inc. (CYBN) Vision Statement of

Cybin Inc. is a biopharmaceutical company focused on progressing psychedelic therapeutics. Understanding their mission, vision, and core values provides insight into their strategic goals and operational priorities. As of April 2025, here's an overview based on available information.

Cybin's mission is centered on developing psychedelic-based therapeutics to address mental health disorders. While a specific, formally declared mission statement isn't explicitly available in the search results, their activities and focus indicate a mission to:

• Advance innovative treatments for mental health conditions using psychedelic compounds.
• Conduct rigorous clinical trials to validate the safety and efficacy of these treatments.
• Improve patient access to potentially transformative therapies.

This mission is reflected in their research and development efforts, clinical programs, and partnerships within the pharmaceutical and mental health sectors.

Similarly, while a precise vision statement isn't directly provided, Cybin's vision can be inferred from their strategic objectives and long-term goals. Their vision appears to be:

• To lead the way in transforming mental healthcare through the development and commercialization of psychedelic therapeutics.
• To establish psychedelic-based treatments as a mainstream option for patients suffering from depression, anxiety, and other mental health disorders.
• To create significant value for shareholders by pioneering advancements in this emerging field.

This vision is supported by their investments in novel drug formulations, drug delivery technologies, and clinical research initiatives.

Cybin's core values guide their actions and decisions. While not explicitly listed, these values can be discerned from their operational practices and public statements:

• Innovation: A commitment to cutting-edge research and development to create novel therapeutic solutions.
• Integrity: Adherence to the highest ethical and scientific standards in conducting research and clinical trials.
• Patient-Centricity: A focus on improving patient outcomes and quality of life through the development of effective treatments.
• Collaboration: Working with leading researchers, healthcare providers, and patient advocacy groups to advance the field of psychedelic therapeutics.

These values are evident in their collaborations with research institutions and their emphasis on patient safety and efficacy in clinical trials.

For additional information about Cybin, you can explore: Cybin Inc. (CYBN): History, Ownership, Mission, How It Works & Makes Money

Cybin Inc. (CYBN) Core Values of

While specific, explicitly stated core values for Cybin Inc. are not readily available in my search results as of April 2025, we can analyze the company's actions and stated goals to infer the values that guide their operations. Based on available information, key values appear to include innovation, patient-centricity, integrity, and collaboration.

Innovation

Innovation is central to Cybin's mission of developing novel psychedelic-based therapeutics. This is evident in their focus on:

• Drug discovery: Cybin is actively involved in researching and developing new molecules and formulations to improve the efficacy and accessibility of psychedelic treatments.
• Novel delivery methods: The company is exploring innovative drug delivery systems to optimize the therapeutic effects of their compounds.
• Intellectual property: Cybin has been granted multiple patents. For example, they received U.S. Patent No. 11,912,639 for deuterated forms of Tryptamine and Psilocin, covering composition of matter and pharmaceutical compositions, as well as methods for using them to treat neurological and psychiatric disorders.

These efforts reflect a commitment to pushing the boundaries of psychedelic medicine through scientific advancement.

Patient-Centricity

Cybin's activities suggest a strong focus on patient well-being, as demonstrated by:

• Addressing unmet needs: Cybin is focused on developing treatments for mental health conditions with significant unmet needs, such as depression and anxiety disorders.
• Clinical trials: The company is conducting clinical trials to evaluate the safety and efficacy of its drug candidates, ensuring that treatments are rigorously tested before being made available to patients.
• Improving treatment outcomes: Cybin is striving to develop therapies that offer improved outcomes and a better quality of life for individuals suffering from mental health issues.

This patient-centric approach underscores their dedication to making a positive impact on the lives of those affected by mental illness.

Integrity

While explicit mentions of 'integrity' as a core value are limited, Cybin's commitment to ethical conduct can be inferred from their:

• Scientific rigor: Cybin emphasizes the importance of rigorous scientific research and adhering to high ethical standards in their clinical trials and drug development programs.
• Transparency: As a publicly traded company, Cybin is subject to regulatory requirements that promote transparency and accountability in their operations.
• Responsible development: Cybin is committed to the responsible development and use of psychedelic therapies, recognizing the potential risks and benefits associated with these substances.

These practices suggest a commitment to upholding the highest standards of integrity in all aspects of their business.

Collaboration

Collaboration appears to be another guiding value, as evidenced by:

• Partnerships: Cybin has established partnerships with research institutions, universities, and other companies to advance their drug development programs.
• Community engagement: The company is actively involved in engaging with the broader scientific and medical community to share knowledge and promote collaboration in the field of psychedelic medicine.

These collaborative efforts demonstrate a recognition that addressing complex challenges in mental health requires a collective approach.

For more information about the company's background, explore: Cybin Inc. (CYBN): History, Ownership, Mission, How It Works & Makes Money